drugset
drugset / Trial / NCT05289830

Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

NCT05289830 ↗

Phase 2 Terminated 4 enrolled Case Comprehensive Cancer Center
RandomizedParallel-groupSingle-blindSupportive care

Summary

Use of antidepressants for participants with localized pancreatic and periampullary cancer receiving neoadjuvant therapy.

Timeline

Start
2022-08-05
Primary completion
2023-08-27
Completion
2023-08-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Escitalopram Small molecule 20 mg —

Indications

pancreatic ductal adenocarcinoma periampullary adenocarcinoma